PT  - JOURNAL ARTICLE
AU  - Zahir Ali
AU  - Rashid Aman
AU  - Ahmed Mahas
AU  - Gundra Sivakrishna Rao
AU  - Muhammad Tehseen
AU  - Tin Marsic
AU  - Rahul Salunke
AU  - Amit K. Subudhi
AU  - Sharif M. Hala
AU  - Samir M. Hamdan
AU  - Arnab Pain
AU  - Norhan Hassan
AU  - Magdy M. Mahfouz
TI  - iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2
AID  - 10.1101/2020.06.02.20117739
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.02.20117739
4099  - http://medrxiv.org/content/early/2020/06/05/2020.06.02.20117739.short
4100  - http://medrxiv.org/content/early/2020/06/05/2020.06.02.20117739.full
AB  - The COVID-19 pandemic caused by SARS-CoV-2 affects all aspects of human life. Detection platforms that are efficient, rapid, accurate, specific, sensitive, and user friendly are urgently needed to manage and control the spread of SARS-CoV-2. RT-qPCR based methods are the gold standard for SARS-CoV-2 detection. However, these methods require trained personnel, sophisticated infrastructure, and a long turnaround time, thereby limiting their usefulness. Reverse transcription-loop-mediated isothermal amplification (RT-LAMP), a one-step nucleic acid amplification method conducted at a single temperature, has been used for colorimetric virus detection. CRISPR-Cas12 and CRISPR-Cas13 systems, which possess collateral activity against ssDNA and RNA, respectively, have also been harnessed for virus detection. Here, we built an efficient, rapid, specific, sensitive, user-friendly SARS-CoV-2 detection module that combines the robust virus amplification of RT-LAMP with the specific detection ability of SARS-CoV-2 by CRISPR-Cas12. Furthermore, we combined the RT-LAMP-CRISPR-Cas12 module with lateral flow cells to enable highly efficient point-of-care SARS-CoV-2 detection. Our iSCAN SARS-CoV-2 detection module, which exhibits the critical features of a robust molecular diagnostic device, should facilitate the effective management and control of COVID-19.Competing Interest StatementID has been filed based on the methods used in this paperFunding StatementThis work was supported, in part, by the Smart Health Initiative at KAUST and the IAF grant from the KAUST IED to MM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We have obtained the necessary ethical approvals from the Saudi MOH and the Mass Gathering directorate in Riyadh for the collection of the samples (MOH Approval #: H-02-K-076-0420-285, dated 13.04.2020; KAUST approval #: 20IBEC14) by AP.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the supplementary information.